SCHEMBL6441939

SCHEMBL6441939

N#Cc1c(OCc2ccccn2)nc(N)nc1Oc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGMT P16455 2/20 0.48
MEN1 O00255 3/20 0.44
ALDH1A1 P00352 3/20 0.44
KMT2A Q03164 3/20 0.44
HPGD P15428 1/20 0.44
CYP1A2 P05177 2/20 0.44
CYP2C19 P33261 2/20 0.44
CYP2C9 P11712 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
TLR7 Q9NYK1 2/20 0.40
TLR8 Q9NR97 1/20 0.40
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39
SQOR Q9Y6N5 1/20 0.38
PIN1 Q13526 1/20 0.38
PARP10 Q53GL7 1/20 0.38
ADORA2A P29274 3/20 0.38
ADORA1 P30542 3/20 0.38
NPC1 O15118 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6441414 0.91 MGMT (0.55) MGMTALDH1A1CYP1A2SMN1; SMN2TLR7
SCHEMBL6443037 0.88 SQOR (0.51) MGMTCYP1A2CYP2C19CYP2C9L3MBTL1
SCHEMBL5041645 0.83 ADORA1 (0.57) MGMTSQORADORA2AADORA1ADORA2B
SCHEMBL6441885 0.82 MGMT (0.53) MGMTALDH1A1CYP1A2SMN1; SMN2TLR7
SCHEMBL6443675 0.81 MGMT (0.48) MGMTMEN1ALDH1A1KMT2AHPGD
SCHEMBL6441951 0.80 MGMT (0.47) MGMTMEN1ALDH1A1KMT2AHPGD
SCHEMBL6441693 0.78 ADORA2A (0.46) MGMTALDH1A1SMN1; SMN2TLR7TLR8
SCHEMBL6443053 0.76 ADORA2A (0.60) MGMTMEN1ALDH1A1KMT2AHPGD
SCHEMBL5041663 0.76 ADORA2A (0.56) MGMTMEN1ALDH1A1KMT2AHPGD
SCHEMBL5044782 0.76 ADORA2A (0.56) MGMTMEN1ALDH1A1KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 MGMT 3075/4885MEN1 4860/4885ALDH1A1 534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.